维普期刊资源整合服务平台（V6.5）

29篇 您的检索式：作者名="Posadas EM"

选中清除导出查看参考文献查看引证文献引用追踪共2页首页上一页第1页下一页末页 /2 跳转

	题名	作者	年代	出处	被引量
1	Proteomic analysis for the early detection and rational treatment of cancer - realistic hope? 显示文摘	Posadas EM Simpkins F Liotta LA	2005	Ann Oncol2005，16，1：	1
2	Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity显示文摘	Azad NS Posadas EM Kwitkowski VE		0，，22：	1
3	Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity显示文摘	Azad NS Posadas EM Kwitkowski VE	2008	J Clin Oncol2008，26，：	1
4	Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity 显示文摘	Azad NS Posadas EM Kwitkowski VE etal	2008	J Clin Oncol2008，26，22：	1
5	A Phase Ⅱ and Pharmacodynamic Study of Gefitinib in Patients with Refractory or Recurrent Epithelial Ovarian Cancer显示文摘	Posadas EM Liel MS Kwitkowski V	2007	Cancer2007，109，7：	1
6	Proteomic analysis for the early detection and rational treatment of cancer-realistic hope?显示文摘	Posadas EM Simpkins F Liotta LA	2005	Ann Oncol2005，16，：	1
7	Proteomics and ovarian canc- er: Implications for diagnosis and treatment: A critical review of the recent literature 显示文摘	Posadas EM Davidson B Kohn EC	2004	Curr Opin Oncol2004，16，5：	1
8	1 Proteom ic analysis for the early detection and rational treatment of cancer-realistic hope显示文摘	Posadas EM Simpkins F Liotta LA et a	2005	AnnOncol2005，16，1：	1
9	Proteomies and ovarian cancer:implications for diagnosis and treatment:a critical review the re-cent literature显示文摘	Posadas EM Davidson B Kohn EC	2004	Curr Opin Oncol2004，16，5：	1
10	Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity显示文摘	Azad NS Posadas EM Kwitkowski VE	2008	J Clin Oncol2008，26，22：	1
11	A phase Ⅱ and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer 显示文摘	Posadas EM Liel MS Kwitkowski V	2007	Cancer2007，109，7：	1
12	A phase Ⅱ and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer 显示文摘	Posadas EM Lie! MS Kwitkowski V	2007	Cancer2007，109，7：	1
13	FYN is overexpressed in human prostate cancer显示文摘	Posadas EM Al-Ahmadie H Robinson VL	2009	BJU Int2009，103，2：	1
14	A prospective analysis of imatinib-induced c-KIT modulation in ovarian cancer:a phase Ⅱ clinical study with proteomic profiling显示文摘	Posadas EM Kwitkowski V Kotz HL	2007	Cancer2007，110，：	1
15	Proteomics and ovarian cancer:implications for diagnosis and treatment:a critical review of the recent literature显示文摘	Posadas EM Davidson B Kohn EC	2004	Curr Opin Oncol2004，16，：	1
16	Proteomics and ovariancancer:impU cations for diagnosis and treatment:a critical review therecent literature显示文摘	Posadas EM Davidson B Kohn EC	2004	Curt Opin Oncol2004，16，5：	1
17	Proteomics andovarian cancer: implications for diagnosis and treatment acritical review the recent literature 显示文摘	Posadas EM Davidson B Kohn EC	2004	Curr Opin Oncol2004，16，5：	1
18	Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity 显示文摘	Azad NS Posadas EM Kwitkowski VE	2008	J Clin Oncol2008，26，22：	1
19	A phase Ⅱ study of ixabepilone (BMS-247550) in metastatic renal-cell carcinoma 显示文摘	POSADAS EM UNDEVIA S MANCHEN E	2007	Cancer Biol Ther2007，6，4：	1
20	Proteomics and ovarian cancer: implications for diagnosis and treatment : a critical review the recent literature显示文摘	Posadas EM Davidson B Kohn EC	2004	Curr Opin Oncol2004，16，5：	1

返回顶部每页显示：

共2页首页上一页第1页下一页末页 /2 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示